Abdel-Wahab et al. TCZ in combo with ipilimumab/nivolumab. Very preliminary results of what will be important trial. Appears safe and well-tolerated with no increased risk cancer progression. @RheumNow #ACR22 Abstr#1670 https://t.co/uPBnHJ9BRH